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Highlights 
 
 HIV-1 TDR among newly diagnosed individuals is 10.7% in Hungary. 
 The prevalence of TDR in Hungary is 9.5% for NRTIs, 1.2% for NNRTIs 
and 0.6% for PIs. 
 Ongoing spread of resistant strains may increase the prevalence of TDR in 
Hungary. 
 
Abstract 
Objectives: Transmitted HIV-1 drug resistance (TDR) may affect the success of 
first-line antiretroviral treatment. The aim of this study was to monitor the 
presence of HIV-1 strains carrying transmitted drug resistance-associated 
mutations (TDRMs) in newly diagnosed, treatment-naïve patients in Hungary. 
Methods: 168 HIV-infected individuals diagnosed between 2013 and 2017 were 
included in the study; most of them (93.5%) belonged to the homo/bisexual 
population. HIV-1 subtypes and TDRMs were determined by analysing the 
protease and reverse transcriptase coding regions of the pol gene by the Stanford 
HIV Drug Resistance Database. Transmission clusters among patients were 
identified using phylogenetic analysis.  
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Results: Although subtype B HIV-1 strains were predominant (87.5%), non-B 
subtypes including F, A, CRF01_AE, CRF02_AG, D and G were also recorded, 
especially in young adults. The overall prevalence of TDR was 10.7% (18/168; 
95% CI: 6.9-16.3%). Subtype B HIV-1 strains carried most of the TDRMs 
(94.4%). Nucleoside reverse transcriptase inhibitor (NRTI)-associated mutations 
were the most prevalent indicators of TDR (16/168; 9.5%; 95% CI: 5.9-14.9%), 
followed by mutations conferring resistance to non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) (2/168; 1.2%; 95% CI: 0.3-4.2%) and protease 
inhibitors (PIs) (1/168, 0.6%; 95% CI: 0.1-3.3%). Phylogenetic analysis revealed 
that most NRTI-associated resistance mutations were associated with a single 
monophyletic clade, suggesting early single source introduction and ongoing 
spread of this drug resistant HIV-1 strain.  
Conclusions: Onward transmission of drug resistant subtype B HIV-1 strains 
accounted for the majority of TDRs observed among treatment-naïve HIV-
infected individuals in Hungary.    
 
Keywords: HIV-1, transmitted drug resistance, Hungary, transmission cluster, 
ongoing transmission 
 
1. Introduction 
Human immunodeficiency virus (HIV), the causative agent of acquired 
immunodeficiency syndrome (AIDS), represents a serious global health 
AC
CE
PT
ED
 M
AN
US
CR
IPT
4 
 
challenge: it is estimated that in 2017, 940 000 people died of AIDS-related 
diseases globally, and AIDS is still the 4th most common cause of death in low-
income countries [1,2]. Although antiretroviral therapy (ART) has significantly 
reduced morbidity and mortality in HIV-infected patients, the development of 
drug resistance poses a threat to the long-term success of ART [3]. Transmission 
of drug resistant strains to therapy-naïve individuals could cause first-line 
regimen treatment failure. Thus, international guidelines recommend testing for 
transmitted drug resistance associated mutations (TDRMs) before initializing 
ART of treatment-naïve patients either with acute or chronic HIV-1 infection 
[4,5].  
Hungary is a country of low HIV prevalence, even though the annual 
number of newly diagnosed HIV infections increased from 0.62 in 2003 to 2.75 
in 2015, per 100 000 population. Between 1985 and 2017, altogether 3567 HIV-
infected persons were diagnosed in Hungary, a country of 10 million, and the 
cumulative number of registered AIDS cases was 944. The main route of HIV 
infection is homo/bisexual contact and the proportion of males is 88% among 
HIV-positive patients with known gender [6].  
In the era of combination antiretroviral therapy (cART), HIV-associated 
death decreased significantly in Hungary, similarly to other European countries. 
Treatment standards of HIV-positive patients are according to Hungarian 
guidelines which are in accordance with the recommendations of European AIDS 
Clinical Society [7]. cART is offered to each HIV-positive patient irrespective of 
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their CD4+ T cell count and it is estimated that at present more than 1900 patients 
receive cART in Hungary.  
Because only limited information was available about the molecular 
epidemiology of HIV-1 in Hungary, we aimed to monitor circulating HIV-1 
subtypes, assess the prevalence of transmitted drug resistance (TDR), and reveal 
potential transmission clusters among treatment-naïve, HIV-1-infected 
individuals in Hungary. 
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2. Materials and Methods 
2.1. Study population  
 Peripheral blood samples were collected between 2013 and 2017, within 1 
year (median: 0.7 month; interquartile range, IQR: 0.36-1.13 months) of HIV 
diagnosis from 168 patients attending the Dermatology, Venereology and 
Dermatooncology Clinic of Semmelweis University, Budapest and the Center for 
HIV, South-Pest Central Hospital, Budapest. South-Pest Central Hospital hosts 
the only Center for HIV in the country, where 98% of HIV-infected patients are 
treated. All patients were newly diagnosed and antiretroviral therapy-naïve, and 
all of their data were anonymized. This study has been approved by the 
Institutional Bioethics Committee of South-Pest Central Hospital and by Medical 
Research Council, Scientific and Research Ethics Committee, Budapest, 
Hungary.  
 
2.2. Sample preparation and sequencing 
Plasma of ART-naïve HIV-1-infected patients was obtained from EDTA-
anticoagulated whole blood samples, centrifuged at 10 000 rpm for 2 min and 
stored at -80°C. Viral RNA was extracted from plasma using the NucliSENS 
miniMAG nucleic acid purification system and specific magnetic extraction 
reagents (bioMérieux, Marcy l'Etoile, France). The protease (PR) and reverse 
transcriptase (RT) coding regions of the pol gene, which are potentially affected 
by drug resistance related mutations were reverse transcribed using RobusT II 
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(Finnzymes, Espoo, Finland), AccessQuick (Promega, Madison, WI, USA) and 
SuperScript III  (Invitrogen, Carlsbad, CA, USA) one-step RT-PCR kits and 
further amplified by nested PCR as described earlier [8,9]. Purified PCR products 
were subjected to direct sequencing using the DYEnamic ET Dye Terminator 
Cycle Sequencing (Amersham Biosciences, Buckinghamshire, UK) and BigDye 
Terminator v3.1 Cycle Sequencing (Applied Biosystems, Foster City, CA, USA) 
kits. Capillary electrophoresis and base calling was implemented by MegaBACE 
1000 (Amersham Biosciences) and Applied Biosystems 3500 Genetic analyser 
systems. 
HIV-1 RNA quantification was performed using the NucliSENS nucleic 
acid purification and amplification system (bioMérieux, Marcy l'Etoile, France) 
according to the manufacturer’s instructions. 
 
2.3. Subtyping and drug resistance interpretation 
For HIV-1 subtype determination, the PR and RT coding sequences were 
analysed using the Stanford HIVDB subtyping program and the COMET tool 
[10,11]. The presence and clinical relevance of TDRMs in the examined samples 
were assessed by the Stanford HIV Drug Resistance Database algorithm 
according to the WHO Surveillance Drug Resistance Mutations list [10,12].  
 
2.4. Phylogenetic and statistical analysis 
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In addition to the 168 sequences newly reported in this study, in the 
phylogenetic analyses we included a further 30 partial pol sequences that we 
reported earlier from Hungary [8]. To enable the identification of transmission 
clusters local to the country, we constructed a set of background control 
sequences by pooling the 5 most similar NCBI BLASTN search results 
(excluding our sequences already submitted to GenBank from Hungary) for each 
of our 198 partial pol sequences [13], then removing duplicate sequences. Some 
samples had been amplified to yield two contigs (covering PR and partial RT, 
respectively); these were concatenated (inserting indeterminate ‘N’ nucleotides in 
the missing positions based on alignment to the HXB2/K03455 reference 
sequence) before submitting to the BLAST search. The combined set of 
Hungarian and background sequences was aligned using MAFFT version 7.212 
[14], followed by manual inspection and correction of the multiple alignment 
using Unipro UGENE version 1.31.1 [15], and the removal (gap-stripping) of 
nucleotide positions that were absent or indeterminate in at least 50% of the 
Hungarian sequences or of the combined set. This procedure resulted in a 
multiple alignment covering HXB2 positions 2253-3379 (codons PR1-RT277), 
with a 63-bp gap between codons RT12-33 where data were missing for samples 
that had been amplified with two contigs; the total length of the alignment was 
1064 base pairs. Steps of the data pipeline were automated with scripts 
implemented in (Bio)python [16] and R [17]. 
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Maximum likelihood phylogenetic trees were constructed with RAxML 
version 8.2 [18] under the GTRCATI model; branch support values were 
computed based on automated bootstrap replicates (-autoMR method of 
RAxML). 
 Potential transmission clusters were identified by using Cluster Picker 1.2 
[19] with a maximum genetic distance threshold 0.045 nucleotide substitutions 
per site within the cluster and bootstrap support ≥98%. Clades consisting of at 
least 3 Hungarian sequences were assigned as transmission clusters. To examine 
the effect of the genetic distance threshold on the number and size of clusters, 
two more stringent thresholds, namely 0.03 and 0.02 nucleotide substitutions per 
site were also investigated. 
The 95% confidence interval of the prevalence of TDR was calculated 
using Wilson score interval [20]. Fisher’s exact test was used to compare 
frequencies between groups; temporal trends and multivariate analyses of the 
prevalence of HIV-1 subtypes and TDR were tested by logistic regression. All 
statistical tests were performed with R version 3.5.0 [17]. Statistical significance 
was defined at p value ≤0.05. 
 
3. Results 
3.1. Characteristics of study population 
A total of 168 therapy-naïve patients diagnosed as HIV-1 positive between 
2013 and 2017 were analysed. The majority of the patients were men who have 
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sex with men (MSM; 157/168; 93.5%), while heterosexual transmission was 
recorded in 11 (11/168; 6.5%) cases. The majority of the patients were male 
(161/168; 95.8%). The median age of the study group was 36 years (IQR: 29-43 
years). At the time of resistance testing the median viral load was 63 500 
copies/ml (IQR: 14 000-265 000 cps/ml) and the median CD4+ T cell count was 
381 cells/μl (IQR: 220-564 cells/μl). The characteristics of the study population 
are summarized in Table 1.   
 
3.2. HIV-1 subtyping 
According to subtyping analysis of the RT and PR coding regions the 
majority of patients carried subtype B HIV-1 strains (147/168; 87.5%), while 
subtype F (7/168; 4.2%), A (6/168; 3.6%), CRF01_AE (3/168; 1.8%), 
CRF02_AG (3/168; 1.8%), D (1/168; 0.6%) and G (1/168; 0.6%) was also 
detected (Figure 1/A). The occurrence of non-B subtypes was significantly 
associated with female gender (p=0.043), and with young adults (20-29 years of 
age, age group II) versus all other adult age groups (age groups III-V; p=0.019; 
Table 1). The most prevalent non-B subtypes among young adults (20-29 years, 
age group II) were A (4/49; 8.2%), F (4/49; 8.2%), CRF02_AG (2/49; 4.1%) and 
G (1/49; 2.0%). The prevalence of HIV-1 subtypes showed no significant 
association with the route of transmission or CD4+ T cell number at diagnosis 
(Table 1).  
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The annual prevalence of non-B subtypes increased significantly among 
treatment-naïve individuals in the studied period (p=0.008; Figure 1/A). This 
association remained significant when further co-factors (age or age group; 
gender) were considered in multivariate tests, or when the test was restricted to 
the male majority group. 
 
3.3. Prevalence and patterns of transmitted drug resistance 
The overall prevalence of transmitted drug resistance was 10.7% (18/168; 
95% CI: 6.9-16.3%) in the 168 patients studied. The most frequently observed 
indicators of TDR were NRTI mutations (16/168; 9.5%; 95% CI: 5.9-14.9%), 
followed by NNRTI (2/168; 1.2%; 95% CI: 0.3-4.2%) and PI mutations (1/168, 
0.6%; 95% CI: 0.1-3.3%; Table 2). The majority of TDRMs were detected in 
samples carrying subtype B HIV strains (17/18, 94.4%; Table 1), whereas a 
M230L NNRTI-associated resistance mutation was identified in a CRF02_AG 
strain. Tests of independence revealed no association between the presence of 
primary resistance mutations and any of gender, age group, route of transmission 
or CD4+ T cell count (Table 1). Logistic regression analyses on the year of 
diagnosis found no temporal trend in the frequency of drug resistance in newly 
diagnosed infections for either the most frequent NRTI class, or when the 
occurrence of any drug resistance associated mutation was considered (p=0.73 
and 0.70, respectively; Figure 1/B). 
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The most frequent NRTI mutation was T215E, which occurred in 
combination with either M41L (11 cases) or L210W (1 case), respectively (Table 
2). In 3 sequences T215E occurred alone and the NRTI mutation F77L was also 
detected in 1 sequence. One patient carried the M230L NNRTI surveillance drug 
resistance mutation (SDRM). Concomitance of K101E NNRTI SDRM and 
E138A polymorphic accessory mutation was identified in another patient.  
We noticed that one patient carried, in addition to the NRTI resistance 
mutations M41L and T215E, the PI major mutation M46L, too (Table 2). As far 
as we know, this is the first observation of a PI major mutation in an ART-naïve 
patient in Hungary. Triple class resistance was not observed. 
 
3.4. Phylogenetic analysis 
To maximize the scope of the comparison, in the phylogenetic analyses we 
included 30 partial pol sequences reported in our earlier study [8], in addition to 
the 168 sequences reported in this study. Phylogenetic and cluster analysis of the 
partial pol sequences revealed 21 possible transmission clusters containing at 
least 3 Hungarian sequences with a strong phylogenetic support (bootstrap value 
≥98%, maximum genetic distance less than 0.045 nucleotide substitutions per 
site) (Figure 2), among which 10 clusters included only Hungarian sequences. 
The size of clusters ranged between 3 and 17. Among the 168 newly diagnosed 
patients from our present study and 30 further patients from our earlier study, 115 
(58.1%) were identified as part of transmission clusters with this definition. The 
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majority of clustered Hungarian patients were male (99.1%), belonged to the 
MSM population (95.7%) and carried subtype B HIV-1 strains (94.8%). 56.5% 
(13/23) of Hungarian samples carrying TDRMs from the present and our earlier 
study were part of any (in total three) transmission clusters. Cluster II contains 7 
Hungarian sequences carrying M41L, T215E NRTI associated resistance 
mutations (Figure 2/A). Cluster III is composed of two Hungarian sequences 
carrying M41L, T215E mutations and an additional Hungarian sequence carrying 
T215E mutation only. The third cluster (Cluster I) carrying only resistant 
Hungarian sequences consists of two sequences with T215E, and an additional 
sequence with L210W and T215E NRTI associated resistance mutations. Clade 
A, a monophyletic group, was formed by all of the Hungarian samples carrying 
NRTI-associated resistance mutations M41L and T215E derived from our present 
(11 samples) and earlier (3 samples) study and an additional sample carrying only 
T215E mutation [8] (Figure 2/A and B). Although bootstrap support was 100% 
and mean genetic distance was 0.024 within Clade A, the maximum genetic 
distance was higher than 0.045 substitutions per site therefore this group was not 
identified as a cluster. 
Among Hungarian samples with non-B subtypes, two clusters were 
identified, three samples with subtype A (Cluster V) and three samples with 
subtype F (Cluster IV) were classified together (Figure 2/A). 
In a more sensitive analysis, stricter criteria on the genetic distance were 
also examined. Cluster analysis with ≥98% bootstrap support and thresholds of 
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0.03 or 0.02 nucleotide substitutions per site decreased the proportion of clustered 
Hungarian samples to 41.1% and 29.3%, respectively. The fraction of resistant 
Hungarian samples in clusters decreased to 21.7% applying either of stricter 
thresholds. 
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4. Discussion 
Analysis of RT and PR coding regions of 168 newly diagnosed, therapy-
naïve HIV-1 positive patients showed that similar to our earlier results, subtype B 
is still the predominant HIV-1 subtype in Hungary [8,21], although the 
prevalence and heterogeneity of non-B subtypes and circulating recombinant 
forms has increased in recent years (Figure 1/A), especially in young adults 
(Table 1). This observation may reflect the increasing diversity of HIV-1 strains 
in Europe and in the neighbouring countries [22-29]. Although subtype B strains 
still predominate in the border countries Slovenia, Austria, Slovakia, Croatia, and 
Serbia, subtype F and A strains are the most prevalent in Romania and Ukraine, 
respectively [23-29]. We emphasize, however, that non-B subtypes have not 
made a significant contribution to TDR in Hungary, because the majority of 
TDRMs were detected in samples carrying subtype B HIV strains (17/18, 94.4%; 
Table 1). We also note that in the present study we had no information on the 
ethnicity or country of origin of the infected patients in the study population, and 
we therefore cannot reliably deduce the contribution of imported cases to the 
increasing prevalence of non-B subtypes. 
In our current study the overall prevalence of TDR was 10.7% (Table 1), 
whereas we previously recorded a prevalence of 16.6% among HIV-infected 
patients diagnosed between 2008 and 2010 [8]. The lower number of cases 
examined and the different time period may explain the higher TDR prevalence 
in our earlier study.  
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In Europe, TDR was fairly stable between 2002 and 2010, and an 8.3% 
overall prevalence was reported in the SPREAD program between 2008 and 2010 
by Hofstra et al. [30]. TDRMs associated with NRTIs were recorded most 
frequently (4.5%). In the present study we observed a higher prevalence of drug 
resistant HIV-1 strains carrying NRTI-associated resistance mutations (9.5%). Of 
note, Hofstra et al. reported a higher prevalence of NRTI-associated resistance 
mutations in the MSM population than among heterosexuals (5% vs. 3.7%) and a 
significantly higher prevalence in subtype B HIV-1 strains compared to non-B 
subtypes (5.6% vs. 2.1%) [30]. Moreover, Frentz et al. reported 11.1% TDRM 
prevalence in a MSM population compared to 6.6% prevalence in heterosexuals 
diagnosed between 2002 and 2007 [31]. These observations fit well to our data 
because in Hungary the main route of HIV infection is homo/bisexual contact and 
the predominant HIV-1 subtype is subtype B.  
In Hungary, similar to data from other European countries, the most 
frequently observed TDRM was M41L, accompanied with T215E (a T215Y or 
T215F revertant mutation). This selection of thymidine analogue mutations may 
have been associated with extensive exposure to the NRTIs zidovudine and 
stavudine in the pre- and early cART era.  
In neighbouring countries, studies on the prevalence of HIV TDRMs have 
yielded variable results. In Romania, a declining trend of TDRMs was observed 
among patients infected predominantly with HIV subtype F1, from 26.08% in 
1997-2004 to 7.89% in 2005-2011 [28]. In Croatia, between 2006 and 2008, 
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Grgic et al. detected surveillance drug resistance mutations in 26 of 118 patients 
(22%) with a pronounced association with NRTIs (19.5%) [26]. The lowest 
prevalence of TDR in the neighbouring countries was observed in Slovenia: in a 
six year period (2011-2016) only four out of 168 (2.4%) patients carried viruses 
with TDRM, followed by 8.0% in Austria from 2003 to 2017 and 8.8% in Serbia 
between 2002 and 2011 [23,24,27].  
Our phylogenetic analysis identified possible transmission clusters with 
relatively small maximum genetic distance and high support. In addition, our 
analysis revealed a monophyletic group (designated Clade A; Figure 2/A and B) 
formed by all of the M41L, T215E carrying strains detected between 2010 and 
2017 in our previous and current study, and an additional strain carrying only 
T215E mutation [8]. Classification of these sequences in a single clade suggests 
an early single source introduction and ongoing forward spread of this resistant 
strain in Hungary (Figure 2/A and B). We speculate that the long time interval of 
onward transmission, from 2010 to 2017, allowed a longer evolutional history of 
the virus, resulting in a higher maximum genetic distance within this group, while 
the apparently successful transmission of this strain might indicate either a 
relatively high fitness (due to potential compensatory mutations), or spreading in 
a high risk population where environmental factors facilitate HIV transmission. 
Clade A, together with Cluster I, significantly contributed to the comparatively 
high overall prevalence of TDR recorded among the untreated, HIV-1-infected 
individuals of the current study. 
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The longer time interval (2008-2017) of the studied Hungarian samples in 
the phylogenetic analysis allowed the use of permissive criteria for transmission 
clusters. Since the definition of a cluster is not clearly determined in the scientific 
literature, we applied less stringent as well as stringent genetic distance 
thresholds, similarly to the work of Pineda-Peña et al. [32]). While the number of 
clustered Hungarian sequences with or without TDRMs decreased with more 
stringent genetic distance thresholds of 0.03 or 0.02, the classification of the 
majority of samples carrying TDRMs into a single monophyletic group suggests 
the forward spread of these resistant HIV-1 strains in Hungary.  
The detected clusters of non-B subtypes may indicate that the introduction 
of subtype A strains (cluster V, Figure 2A) and subtype F strains (cluster IV, 
Figure 2A) to the Hungarian population was possibly followed by forward spread 
within the young age group (age group II, Table I), resulting in  a higher 
prevalence of non-B subtypes among young patients. 
This study draws attention to the fact that every tenth newly diagnosed, 
HIV-1-positive patient is expected to carry a partially drug resistant HIV-1 strain 
in Hungary. Pre-treatment testing of HIV drug resistance contributes to the 
effective, personalized therapy of patients. With a well-chosen first-line 
antiretroviral therapy viral suppression can be achieved reliably, reducing the 
transmission of HIV at the population level, and aiding the completion of the 
second and third 90 future targets of Joint United Nations’ 90-90-90 action plan, 
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namely 90% of HIV-positive people on antiretroviral therapy and 90% of viral 
suppression among treated people by 2020 [33]. 
In conclusion, our data showed that in recent years the overall prevalence 
of TDR was 10.7% among newly diagnosed, therapy-naïve HIV-1-infected 
individuals in Hungary. This value is somewhat higher than the corresponding 
HIV-1 TDR prevalence in most European countries, possibly due to the forward 
spread of one efficiently transmitted drug resistant strain in at least the last 7 
years in this country. The changing patterns of HIV-1 TDR in Hungary, its 
neighbours, and other countries indicate the necessity of continuous monitoring 
of TDRMs in newly infected individuals. The appearance of HIV-1 subtypes, 
circulating recombinant forms and drug resistance mutations not detected in 
previous studies in Hungary indicates the diversification of the epidemic, and 
also underlines the importance of a continuous molecular surveillance.  
 
Sequence Data 
 The nucleotide sequences reported in this study have been submitted to 
GenBank Nucleotide Sequence Database under accession numbers KX999940-
KX999999, KY967234-KY967255, MK236491-MK236537 (RT sequences); 
KY021932-KY021991, KY950415-KY950436, MK213272-MK213318 (PR 
sequences) and MK250657-MK250695 (PR+RT sequences). 
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Figure Legends  
Figure 1. Temporal trends of HIV-1 subtypes (A) and TDR (B) detected in 
the studied Hungarian samples.  
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Figure 2. Phylogenetic relations and transmission clusters based on partial 
pol regions of HIV-1 strains from Hungary. (A) A Maximum likelihood 
phylogenetic tree is shown, composed of 168 HIV-1 sequences derived from our 
present study, 30 sequences from our earlier study, and corresponding 
background sequences. Colour code: purple lines indicate Hungarian sequences 
from the present study carrying transmitted drug resistance-associated mutations 
(TDRMs);  orange lines indicate Hungarian sequences carrying TDRMs from 
our earlier study (2008 to 2010, [8]); blue lines indicate Hungarian sequences 
from the present study without drug resistance-associated mutations; green lines 
indicate Hungarian sequences without drug resistance-associated mutations from 
our earlier study (2008 to 2010, [8]); black lines indicate background sequences. 
Yellow-highlighted squares designate possible transmission clusters. Pink-
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highlighted squares designate possible transmission clusters of Hungarian 
sequences carrying TDRMs. Potential transmission clusters were identified with 
bootstrap support ≥98% and maximum genetic distance less than 0.045 
nucleotide substitutions per site. A green-highlighted square designates Clade A, 
composed of all Hungarian sequences carrying M41L and T215E TDRMs, and a 
single sequence carrying T215E only. To show the sensitivity of the 
identification of clusters to the choice of the genetic distance threshold, potential 
transmission clusters with bootstrap support ≥98% and maximum genetic 
distance less than 0.02 nucleotide substitutions per site are highlighted with blue 
squares. Identified TDRMs are indicated next to the corresponding tips of the 
cladogram. (B) An enlarged picture of the subtree corresponding to Clade A is 
shown. Clade A contains Hungarian sequences from the present study (2013-
2017, 12 samples) and our earlier study (2010, 3 samples, [8]). All of the 14 
sequences carrying both M41L and T215E TDRMs belong to Clade A, together 
with a single sequence carrying T215E only. Symbols indicate the year of 
diagnosis of HIV-1 infection. 
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Table 1. Characteristics of the study population 
  
Total 
population  
Subtype B  
Non-B 
subtypes§  
  
Patients 
with 
primary 
resistance  
Patients 
without 
primary 
resistance    
  
n % n % n % 
p-
value 
n % n % 
p-
value 
Samples 168  147 87.5% 21 
12.5
%  18 
10.7
% 150 
89.3
%  
Sex             
Male 161 
95.8
% 143 97.3% 18 
85.7
% 0.043* 16 
88.9
% 145 
96.7
% 0.165 
Female 7 
4.2
% 4 2.7% 3 
14.3
%  2 
11.1
% 5 3.3%  
Age  group (years)            
I. <20 0  0  0   0  0   
II. 20-29 49 
29.2
% 38 25.9% 11 
52.4
% 0.019* 6 
33.3
% 43 
28.7
% 0.784 
III. 30-39 60 
35.7
% 55 37.4% 5 
23.8
% 0.330 6 
33.3
% 54 
36.0
% 1.000 
IV. 40-49 39 
23.2
% 37 25.2% 2 9.5% 0.166 4 
22.2
% 35 
23.3
% 1.000 
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V. >50 20 
11.9
% 17 11.6% 3 
14.3
% 0.720 2 
11.1
% 18 
12.0
% 1.000 
Route of 
transmission             
MSM 157 
93.5
% 139 94.6% 18 
85.7
% 0.143 15 
83.3
% 142 
94.7
% 0.099 
HET 11 
6.5
% 8 5.4% 3 
14.3
%  3 
16.7
% 8 5.3%  
CD4+ T cell 
count 
(cells/mm3)  
<200 40 
23.8
% 34 23.1% 6 
28.6
% 0.589 5 
27.8
% 35 
23.3
% 0.770 
≥200 128 
76.2
% 113 76.9% 15 
71.4
%  13 
72.2
% 115 
76.7
%  
MSM: men who have sex with men;  HET: heterosexual contact 
§Non-B subtypes detected in this study: F (7/168; 4.2%), A (6/168; 3.6%), CRF01_AE (3/168; 
1.8%), CRF02_AG (3/168; 1.8%), D (1/168; 0.6%) and G (1/168; 0.6%). 
*Designates statistically significant difference between groups (Fisher’s exact test was used to 
compare frequencies between groups; statistical significance was defined at two-tailed p value 
<0.05). Single age groups were compared with the cumulative data of other age groups.  
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Table 2. Frequency and resistance profile of transmitted drug resistance mutations (TDRMs) detected in ART-naïve 
HIV-1-infected individuals in Hungary 
 
 
NRTI  Resistance profile 
Mutation Number (n, %)  Potential low Low Intermediate High 
M41L, T215E 10 (6.0)   ABC, DDI, TDF AZT, D4T  
T215E 3 (1.8)  DDI AZT, D4T   
L210W, T215E 1 (0.6)   ABC, DDI, TDF AZT, D4T  
F77L 1 (0.6)  AZT, D4T, DDI    
       
NNRTI      
Mutation Number (n, %)      
M230L 1 (0.6)    EFV, ETR DOR, NVP, RPV 
K101E, E138A 1 (0.6)   DOR, EFV, ETR NVP RPV 
       
Dual class (NRTI+PI)      
Mutation Number (n, %)      
M41L, T215E, 
M46L 
1 (0.6)  
ATV, FPV, IDV, LPV, 
SQV, TPV 
ABC, DDI, TDF,  NFV AZT, D4T  
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The presence and the clinical relevance of TDRMs were assessed by the Stanford HIV Drug Resistance Database algorithm 
Version 8.7. 
Bold: transmitted drug resistance mutations (TDRMs)  
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease 
inhibitor; ABC, abacavir; DDI, didanosine; TDF, tenofovir; AZT, zidovudine; D4T, stavudine; EFV, efavirenz; ETR, etravirine; 
DOR, doravirine; NVP, nevirapine; RPV, rilpivirine; ATV, atazanavir; FPV, fosamprenavir; IDV, indinavir; LPV, lopinavir; SQV, 
saquinavir; TPV, tipranavir; NFV, nelfinavir.  
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